.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
US Department of Justice
Chubb
Baxter
Cantor Fitzgerald
Covington
AstraZeneca
Citi
Teva
Federal Trade Commission

Generated: September 25, 2017

DrugPatentWatch Database Preview

Epoprostenol sodium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for epoprostenol sodium and what is the scope of epoprostenol sodium freedom to operate?

Epoprostenol sodium
is the generic ingredient in three branded drugs marketed by Glaxosmithkline Llc, Actelion Pharms Ltd, and Teva Pharms Usa, and is included in three NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Epoprostenol sodium has fifteen patent family members in fourteen countries.

There are seven drug master file entries for epoprostenol sodium. Three suppliers are listed for this compound.

Summary for Generic Name: epoprostenol sodium

Tradenames:3
Patents:2
Applicants:3
NDAs:3
Drug Master File Entries: see list7
Suppliers / Packagers: see list3
Bulk Api Vendors: see list19
Clinical Trials: see list2,404
Patent Applications: see list6,386
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:epoprostenol sodium at DailyMed

Pharmacology for Ingredient: epoprostenol sodium

Ingredient-typeProstaglandins I
Drug ClassProstacycline Vasodilator
Physiological EffectVasodilation
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd
VELETRI
epoprostenol sodium
INJECTABLE;INJECTION022260-002Jun 28, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Teva Pharms Usa
EPOPROSTENOL SODIUM
epoprostenol sodium
INJECTABLE;INJECTION078396-001Apr 23, 2008APRXNoNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-002Sep 20, 1995APRXYesYes► Subscribe► Subscribe► Subscribe
Actelion Pharms Ltd
VELETRI
epoprostenol sodium
INJECTABLE;INJECTION022260-001Jun 27, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Actelion Pharms Ltd
VELETRI
epoprostenol sodium
INJECTABLE;INJECTION022260-001Jun 27, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-001Sep 20, 1995APRXYesYes► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
EPOPROSTENOL SODIUM
epoprostenol sodium
INJECTABLE;INJECTION078396-002Apr 23, 2008APRXNoNo► Subscribe► Subscribe► Subscribe
Actelion Pharms Ltd
VELETRI
epoprostenol sodium
INJECTABLE;INJECTION022260-002Jun 28, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: epoprostenol sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-001Sep 20, 1995► Subscribe► Subscribe
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-002Sep 20, 1995► Subscribe► Subscribe
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-002Sep 20, 1995► Subscribe► Subscribe
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-001Sep 20, 1995► Subscribe► Subscribe
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-001Sep 20, 1995► Subscribe► Subscribe
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-002Sep 20, 1995► Subscribe► Subscribe
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-001Sep 20, 1995► Subscribe► Subscribe
Glaxosmithkline Llc
FLOLAN
epoprostenol sodium
INJECTABLE;INJECTION020444-002Sep 20, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: epoprostenol sodium

Country Document Number Estimated Expiration
HungaryE026166► Subscribe
Portugal1993557► Subscribe
Japan5415771► Subscribe
Denmark1993557► Subscribe
Cyprus1117128► Subscribe
Canada2868998► Subscribe
BrazilPI0707488► Subscribe
Russian Federation2423130► Subscribe
Spain2558705► Subscribe
European Patent Office1993557► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
Express Scripts
Baxter
Cipla
Teva
Novartis
UBS
Mallinckrodt
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot